Back
ESC Premium Access

Systolic blood pressure visit-to-visit variability and clinical outcomes of heart failure with preserved ejection fraction

Session: Chronic heart failure e-posters
Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)
Speaker: Doctor Q. Zhang (Tianjin, CN)
Event: ESC Congress 2021 - The Digital Experience

Presentation

0

About the speaker

Doctor Qi Zhang

Tianjin Chest Hospital, Tianjin (China)
0 follower

218 more presentations in this session

Intermittent therapy with levosimendan in patients with advanced heart failure

Speaker: Professor M. Weis (Munich, DE)

Access
Abstract
Slides
0
Thumbnail

Differences in long-term all-cause and cardiovascular mortality according to heart failure aetiology in ambulatory patients

Speaker: Doctor G. Spitaleri (Badalona, ES)

Access
Abstract
Slides
0
Thumbnail

Comparing the central arterial stiffness indices in the decompensated and compensated states of heart failure: a cohort study

Speaker: Assistant Professor G. Youssef (Cairo, EG)

Access
Abstract
Slides
0
Thumbnail

Opportunities for clinician education in the pharmacotherapy of stable heart failure

Speaker: Doctor P. Murray (Dublin, IE)

Access
Abstract
Slides
0
Thumbnail

The risks and benefits of spironolactone use in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease

Speaker: Mrs O. Obertynska (Vinnitsa, UA)

Access
Abstract
Slides
0
Thumbnail

Access the full session

Chronic heart failure e-posters

Speakers: Doctor Q. Zhang, Professor M. Weis, Doctor G. Spitaleri, Assistant Professor G. Youssef, Doctor P. Murray...
Access
0
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress
logo Image

Related content

ESC Premium Access

Other post-COVID consequences: brain, kidneys and skeletal muscles.

27 August 2021

ESC Premium Access

The long non-coding RNA Heat4 is upregulated in heart failure and decreases the immune response of non-classical monocytes

27 August 2021

ESC Premium Access

Urate lowering therapy is associated with a lower risk of heart failure hospitalisation or mortality in hyperuricaemic patients with heart failure: a comparative effectiveness study

27 August 2021

This platform is supported by

logo Novo Nordisk